EDMUND CHADA BARACAT
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Obstetrícia e Ginecologia, Faculdade de Medicina - Docente
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina - Líder
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina - Líder
43 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 43
conferenceObject Melatonin action on luteal - granulosa cells in women with marital infertility undergoing in vitro fertilization(2016) MAGANHIN, Carla; CARVALHO, Katia; TURCO, Edson Lo; SERAFINI, Paulo; GARCIA, Natalia; CIPOLLA-NETTO, Jose; SIMOES, Manuel; BARACAT, Edmund; SOARES-JUNIOR, Jose Maria- The effects of soybean isoflavones and 17-estradiol in uterus and mammary glands of diabetic rat models(2018) CARBONEL, Adriana Aparecida Ferraz; LIMA, Patricia Daniele Azevedo; LIM, Jung Jin; FUCHS, Luiz Fernando Portugal; PAIOTTI, Ana Paula Ribeiro; SASSO, Gisela Rodrigues da Silva; SIMOES, Ricardo Santos; SOARES JUNIOR, Jose Maria; BARACAT, Edmund Chada; SIMOES, Manuel de JesusThe objective of this study was to evaluate the action of soy isoflavones and 17 beta estradiol on the extracellular matrix in the uterus and mammary gland of diabetic rats. Sixty adult female rats underwent ovariectomy, then randomized into seven groups of ten animals each: Non-diabetic: GI Sham control animals ovariectomized; and GII control ovariectomized that received propylene glycol vehicle. Diabetic: GIII Sham control diabetic animals ovariectomized; GIV ovariectomized diabetic animals receiving propylene glycol vehicle; GV diabetic ovariectomized animals treated with soy isoflavones (150mg/kg by gavage); GVI ovariectomized diabetic rats treated with estrogen (17b-estradiol, 10mg/kg, subcutaneously); GVII diabetic ovariectomized animals treated with soy isoflavones (150 mg/kg by gavage), and with estrogen (17b-estradiol, 10 mg/kg combination therapy). Treatments occurred during 30 consecutive days. After animals euthanasia, a portion of the uterus was immersed in liquid nitrogen for molecular biology analysis, the other portion of uterus and mammary glands were removed and processed for paraffin embedding. Soy isoflavones (GV) and 17b estradiol improved the production of compounds of extracellular matrix, such as small leucine-rich proteoglycans (SLRPs). The combination of both therapies had an additive effect in SLRPs expression. Soy isoflavones contribute to the uterine integrity of SLRPs of diabetic rats.
- Metformin versus lifestyle changes in treating women with polycystic ovary syndrome(2012) CURI, Daniella D. G.; FONSECA, Angela Maggio; MARCONDES, Jose Antonio M.; ALMEIDA, Jose Alcione M.; BAGNOLI, Vicente R.; SOARES- JR., Jose Maria; BARACAT, Edmund ChadaObjective: To compare the efficacy of metformin with that of lifestyle changes in patients with polycystic ovary syndrome (PCOS). Design: Prospective, randomized clinical trial of 40 women with PCOS to analyze the effects of metformin and lifestyle intervention treatments on menstrual pattern and hormone and metabolic profile. The duration of treatment was 6 months. Statistical analysis was done using Student's t-test. Results: Fifteen women in the metformin group and 12 in the lifestyle changes group completed the study. The menstrual pattern improved by similar to 67% in both groups. There was a significant decrease in waist circumference in the lifestyle changes group (101.8 +/- 3.9 and 95.1 +/- 3.6, at baseline and at 6 months of treatment, respectively; p<0.001) and in body mass index (BMI) in both groups. The predictor of menstrual pattern improvement was BMI. Conclusions: Both metformin and lifestyle changes may increase the number of menstrual cycles in PCOS. This effect was related to a decrease in BMI.
conferenceObject Cytoskeleton remodeling and migration of T47D breast cancer cell enhanced by prolactin(2016) SILVA, Priscilla Da; AMARAL, Vinicius Do; BARACAT, Edmund; SOARES- JR., Jose Maria; SIMONCINI, TommasoconferenceObject Gene expression of small leucine-rich proteoglycans (SLRPS) in lacrimal gland of female mice with hyperprolactinemia induced metoclopramide(2016) STAVARE, Ariadne; VERNA, Carina; SIMOES, Ricardo; NADER, Helena; SOARES- JR., Jose; BARACAT, Edmund; GOMES, ReginaconferenceObject GLI transcription factors involvement in leiomyoma genesis(2016) GARCIA, Natalia; ANJOS, Laura; BOZZINI, Nilo; MACIEL, Gustavo; BARACAT, Edmund; CARVALHO, Katia- Etonogestrel-releasing contraceptive implant in a patient using thalidomide for the treatment of erythema nodosum leprosum: a case report(2022) FERREIRA-FILHO, Edson Santos; BAHAMONDES, Luis; DUARTE, Daniele Coelho; GUIMARAES, Ana Lucia Monteiro; ALMEIDA, Patricia Goncalves de; SOARES-JUNIOR, Jose Maria; BARACAT, Edmund Chada; SORPRESO, Isabel Cristina EspositoIntroduction Thalidomide is an immunomodulatory drug and first choice in the treatment of erythema nodosum leprosum. Given its teratogenic potential, it is essential that an effective contraceptive method is used, especially a long-acting reversible contraceptive (LARC) method. The subdermal etonogestrel (ENG)-releasing implant is an adequate method due to the high effectiveness and long-term use. However, interaction between thalidomide and ENG has not been well documented. Concern arises because thalidomide interacts with cytochrome P450 (CYP450) enzymes that metabolize sexual steroids. AIM: We aimed to study the effectiveness and safety of the ENG-implant in a thalidomide user. Methods Case report of a sexually active 21-year-old patient with both Hansen's disease and leprosy reaction type 2 treated with thalidomide requiring effective contraception. Follow-up was up to 36 months after implant placement. Results Contraception with ENG-implant was effective and safe, based on clinical parameters (reduction of menstrual flow and cervical mucus thickening) and laboratory parameters (gonadotropins and sexual steroids). Conclusion To the best of our knowledge, this is the first case reported which presents a patient in simultaneous use of thalidomide and ENG-implant. Although this case report preliminary supports effectiveness and safety of ENG-implant as a contraceptive option in women using thalidomide, rigorous drug-drug interaction research is needed to better characterize the interaction between thalidomide and the ENG-implant.
- Impact of age and body mass on the intensity of menopausal symptoms in 5968 Brazilian women(2013) FONSECA, Angela Maggio Da; BAGNOLI, Vicente Renato; SOUZA, Marilene Alicia; AZEVEDO, Raymundo Soares; COUTO JUNIOR, Euro De Barros; SOARES JUNIOR, Jose Maria; BARACAT, Edmund ChadaObjective: To assess the relationship of onset of menopause and body mass on the menopausal symptoms in post-menopausal Brazilian women. Design: Observational study conducted by the selection and inclusion of 5968 Brazilian women after menopause. The following variables were analyzed in this study: time at menopause; the relationship between age at menarche and age at menopause; vasomotor symptoms compared with age at the time of menopause and the time of menopause; Kupperman menopausal index (KMI) versus total time of menopause; body mass index (BMI) compared to the time of menopause, vasomotor symptoms, and KMI total score. We used the Chi-square test, and the significance level was set at 5%. Results: The age at natural menopause ranged from 41 to 62 years (mean 48.1 +/- 4.07 years). A younger age at menopause was associated with a high intensity of vasomotor symptoms. These symptoms were more intense in the first 5 years of menopause and decreased with time. The KMI total also decreased with time after menopause, with the exception of arthralgia, myalgia, and insomnia, which did not tend to improve over time. In addition, the vasomotor symptoms and total KMI were more frequent with increasing BMI. Conclusions: Our results suggested that the age of menopause and BMI may influence the intensity of vasomotor symptoms.
- Histomorphometric and immunohistochemical changes in interstitial cells and ovarian follicles of rats with polycystic ovaries treated with clomiphene citrate(2021) LOMBARDI, Leonardo Augusto; MATTOS, Leandro Sabara; SIMOES, Ricardo Santos; FLORENCIO-SILVA, Rinaldo; SIMOES, Manuel de Jesus; FRANCO, Paulo Celso; CARBONELL, Adriana Aparecida Ferraz; SASSO, Gisela Rodrigues da Silva; BARACAT, Edmund Chada; SOARES-JR, Jose MariaObjective To evaluate the histomorphometric and immunohistochemical changes in interstitial cells and ovarian follicles of rats treated with clomiphene citrate during and after induction of permanent estrus. Methods Twenty four adult-female rats with regular estrous cycle were equally divided into three groups: (1) GCtrl-at estrous phase. (2) GPCOS-at permanent-estrous phase. (3) GCC-PCOS rats, which remained exposed to 60 days of continuous illumination and treated with Clomiphene Citrate. After that, the animals were euthanized, and the ovaries were removed and processed for paraffin embedding. Sections were stained with H.E. for histomorphometry or subjected to immunohistochemistry for Ki-67 and cleaved caspase-3 detections. Results The GPCOS showed lack of corpus luteum and several ovarian cysts, as well as interstitial-like cells. The presence of corpus luteum and a significant increase in primary and antral follicles were observed in GCC, which also showed a decrease in the number of ovarian cysts and in the area occupied by interstitial-like cells, as well as a decrease in nuclear volume of interstitial cells. The percentage of cell proliferation was significantly higher in granulosa cells of the GCC. On the other hand, the percentage of apoptosis was significantly higher in the granulosa cells of GPCOS than the GCC. Conclusion The ovaries of rats treated with clomiphene citrate showed a decrease in the number of cysts, an increase in the number of ovarian follicles, the presence of corpus luteum along with a decrease in the nuclear volume in the area occupied by interstitial cells.
- Endometriosis doubles the risk of sexual dysfunction: a cross-sectional study in a large amount of patients(2017) FAIRBANKS, Flavia; ABDO, Carmita Helena; BARACAT, Edmund C.; PODGAEC, SergioIntroduction: Endometriosis affects several aspects of a woman's life, including sexual function, but which specific aspects of sexual function remains unclear.Methods: A cross-sectional study was performed involving 1001 women divided into two groups, according to the presence or absence of endometriosis. We assessed sexual function, anxiety and depression of patients and correlated these findings with symptoms, locations and types of endometriosis and the affected domains of sexual function. Eighteen completed the forms incorrectly, 294 women (29.9%) were excluded due to severe anxiety and depression. One hundred and six patients had symptoms that could have any relation to endometriosis, so they were also excluded. The final cohort was composed of 254 patients with endometriosis and 329 patients without the disease. Sexual function score was assessed using the female sexual quotient (FSQ); Beck inventories were used to assess anxiety and depression.Results: Patients with endometriosis were affected in all phases of sexual response: desire, sexual arousal, genital-pelvic pain/ penetration and orgasm/ sexual satisfaction. In the overall assessment, 43.3% of patients with endometriosis had sexual dysfunction, while the population without endometriosis sexual dysfunction occurred in 17.6% of women.Conclusions: Patients with endometriosis have more than twice sexual dysfunctions as compared to women without the disease.